Neuroscientist Searches for Ways to Reduce Seizures in Children

Neuroscientist Searches for Ways to Reduce Seizures in Children

Mutations in the KCNT1 gene can cause severe, treatment-resistant epilepsy in about 3,000 U.S. children. Fralin Biomedical Research Institute scientist Matthew Weston is testing a KCNT1 inhibitor from Actio Biosciences that reduces seizures in mice. If successful, the drug could enter clinical trials by 2026, offering hope for a targeted therapy to improve outcomes.

Actio gets $66M for experimental epilepsy and Charcot-Marie-Tooth treatments

An impressive group of biopharma investors put $66 million into a San Diego startup called Actio Biosciences. The clinical-stage company said Wednesday morning that existing investor Deerfield Management and new backer Regeneron Ventures co-led Actio' ...

All Wales health boards failing to meet first seizure treatment standards – report - Epilepsy Action

Wales health boards are falling below epilepsy healthcare standards, according to findings in the Wales report from Epilepsy Action Cymru.